Quattro Financial Advisors LLC Acquires 22,500 Shares of Moderna, Inc. (NASDAQ:MRNA)

Quattro Financial Advisors LLC boosted its holdings in Moderna, Inc. (NASDAQ:MRNA) by 36.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 84,600 shares of the company’s stock after buying an additional 22,500 shares during the period. Moderna makes up about 0.9% of Quattro Financial Advisors LLC’s investment portfolio, making the stock its 25th largest position. Quattro Financial Advisors LLC’s holdings in Moderna were worth $3,439,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of MRNA. State Street Corp increased its stake in Moderna by 12.1% during the third quarter. State Street Corp now owns 16,847,212 shares of the company’s stock valued at $1,125,899,000 after acquiring an additional 1,823,276 shares during the period. Wellington Management Group LLP grew its holdings in shares of Moderna by 21.0% during the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock worth $349,166,000 after purchasing an additional 906,114 shares in the last quarter. Two Sigma Advisers LP bought a new stake in shares of Moderna during the third quarter valued at approximately $23,825,000. International Assets Investment Management LLC raised its stake in shares of Moderna by 10,687.1% in the third quarter. International Assets Investment Management LLC now owns 319,514 shares of the company’s stock valued at $21,353,000 after purchasing an additional 316,552 shares in the last quarter. Finally, Douglas Lane & Associates LLC lifted its position in Moderna by 62.9% in the fourth quarter. Douglas Lane & Associates LLC now owns 773,804 shares of the company’s stock worth $32,175,000 after purchasing an additional 298,715 shares during the period. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Stock Performance

MRNA stock opened at $32.60 on Friday. The stock has a market capitalization of $12.55 billion, a PE ratio of -5.60 and a beta of 1.59. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. The company has a 50 day moving average price of $40.22 and a 200 day moving average price of $58.87. Moderna, Inc. has a fifty-two week low of $31.94 and a fifty-two week high of $170.47.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.89) by $1.92. The business had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The firm’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.39) earnings per share. Analysts forecast that Moderna, Inc. will post -9.18 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on MRNA. HSBC raised shares of Moderna from a “hold” rating to a “buy” rating and set a $58.00 price target on the stock in a report on Monday, November 18th. Berenberg Bank upped their target price on shares of Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a research note on Thursday, January 16th. Barclays cut their price target on shares of Moderna from $125.00 to $111.00 and set an “overweight” rating for the company in a research note on Friday, November 8th. Jefferies Financial Group lowered their price objective on Moderna from $65.00 to $55.00 and set a “hold” rating on the stock in a research note on Tuesday, October 15th. Finally, Needham & Company LLC restated a “hold” rating on shares of Moderna in a research report on Friday, November 8th. Four equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Moderna currently has an average rating of “Hold” and a consensus price target of $67.26.

Insider Buying and Selling at Moderna

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the company’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the sale, the insider now owns 19,717 shares in the company, valued at approximately $843,690.43. This represents a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In the last three months, insiders have sold 2,664 shares of company stock worth $115,210. Company insiders own 15.70% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.